FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Kisspeptin-10

Metastin 45-54 / KP-10 / KISS1

Sexual Health

Kisspeptin-10 is a truncated, biologically active fragment of the kisspeptin family of peptides, derived from the KiSS-1 gene product. It is the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, directly stimulating GnRH neurons to initiate the reproductive hormone cascade. It is an emerging research compound in reproductive endocrinology, with applications in fertility diagnostics, IVF protocols, and understanding puberty initiation.

Mécanisme d'action

C-terminal decapeptide fragment of kisspeptin that activates GPR54 (KISS1R) receptors on GnRH neurons. Potently stimulates the hypothalamic-pituitary-gonadal (HPG) axis, triggering pulsatile GnRH release and downstream LH and FSH secretion.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Research protocols use 1-10mcg/kg via IV infusion or subcutaneous injection. Single-dose studies commonly use 1nmol/kg IV. Very short-acting; effects on LH occur within minutes.

Notes de recherche

Clinical Research Status

Kisspeptin-10 is in early-phase clinical research primarily at academic centers, with Imperial College London leading human studies for IVF and reproductive disorders. Clinical trials have demonstrated its ability to trigger LH pulses and stimulate oocyte maturation as a potential alternative to HCG triggers in IVF. It is not yet approved for any therapeutic indication but has orphan-like research status in reproductive medicine.

Key Published Findings

Human studies demonstrate that kisspeptin-10 infusion (at doses of 0.1-1.0 nmol/kg) potently stimulates LH and FSH secretion in healthy volunteers and patients with reproductive disorders. In IVF contexts, kisspeptin-triggered oocyte maturation has produced viable pregnancies with theoretically lower risk of ovarian hyperstimulation syndrome compared to HCG triggers. Research confirms kisspeptin neurons are the critical gatekeepers of puberty onset, integrating metabolic and circadian signals to initiate HPG axis activation.

Safety Profile

Kisspeptin-10 has demonstrated an excellent safety profile in human clinical studies, with no serious adverse events reported across multiple Phase 1/2 trials. Its short half-life (approximately 4-5 minutes for kisspeptin-10) means effects are rapidly reversible, reducing risk of prolonged overstimulation. Unlike HCG triggers in IVF, kisspeptin stimulation produces a more physiological gonadotropin surge that may reduce ovarian hyperstimulation syndrome risk.

Comparison to Related Compounds

Unlike gonadorelin which directly activates GnRH receptors on the pituitary, kisspeptin acts one step further upstream by stimulating GnRH neurons themselves, producing a more physiological hormonal cascade. Compared to HCG for IVF triggering, kisspeptin produces a shorter and more physiological LH surge. The kisspeptin-54 (full-length) form has a longer half-life than kisspeptin-10 but both activate the same GPR54 (KISS1R) receptor.

Community Observations

Kisspeptin-10 has attracted interest from reproductive endocrinology researchers as a potentially safer alternative for IVF trigger protocols, particularly in OHSS-prone patients. The peptide's position at the apex of the HPG axis makes it a uniquely informative diagnostic tool for distinguishing hypothalamic from pituitary causes of hypogonadism. Its extremely short half-life currently limits practical therapeutic applications outside of controlled clinical settings.

Moitié de vie

~28 minutes

Réconstitution

Sterile saline or bacteriostatic water

Conservation

Lyophilisé

Store at -20C for long term.

Réconstitué

Refrigerate 2-8C. Use within 7 days.

Statut légal aux États-Unis

Research chemical (not FDA-approved)

Autres noms connus

Metastin 45-54KP-10KISS1

Questions fréquentes

Qu'est-ce que Kisspeptin-10 ?

Kisspeptin-10 is a truncated, biologically active fragment of the kisspeptin family of peptides, derived from the KiSS-1 gene product. It is the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, directly stimulating GnRH neurons to initiate the reproductive hormone cascade. It is an emerging research compound in reproductive endocrinology, with applications in fertility diagnostics, IVF protocols, and understanding puberty initiation.

Comment agit Kisspeptin-10 ?

C-terminal decapeptide fragment of kisspeptin that activates GPR54 (KISS1R) receptors on GnRH neurons. Potently stimulates the hypothalamic-pituitary-gonadal (HPG) axis, triggering pulsatile GnRH release and downstream LH and FSH secretion.

Quel est le statut réglementaire de Kisspeptin-10 aux États-Unis ?

Research chemical (not FDA-approved)

Quelle est la demi-vie de Kisspeptin-10 ?

~28 minutes

Sous quels autres noms Kisspeptin-10 est-il connu ?

Metastin 45-54, KP-10, KISS1

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète